My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 177

    1.

    Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

    Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA.

    Diabetes Care. 2006 Mar;29(3):510-4.PMID: 16505497 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.

    Basu A, Jensen MD, McCann F, Nandy D, Mukhopadhyay D, McConnell JP, Rizza RA.

    Endocr Pract. 2007 Mar-Apr;13(2):147-52.PMID: 17490928 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.

    Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA.

    Metabolism. 2005 Jan;54(1):24-32.PMID: 15562376 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.PMID: 12050251 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    6.

    Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.

    Kushner RF, Sujak M.

    Obesity (Silver Spring). 2009 May;17(5):1017-22. Epub 2009 Jan 29.PMID: 19180065 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.

    Cefalu WT, Schneider DJ, Carlson HE, Migdal P, Gan Lim L, Izon MP, Kapoor A, Bell-Farrow A, Terry JG, Sobel BE.

    Diabetes Care. 2002 Dec;25(12):2123-8.PMID: 12453948 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.

    Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T.

    Diabetes Technol Ther. 2008 Jun;10(3):206-12.PMID: 18473695 [PubMed - indexed for MEDLINE]Related articles

    9.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.

    Metabolism. 2007 Oct;56(10):1418-24.PMID: 17884455 [PubMed - indexed for MEDLINE]Related articles

    11.

    Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.

    Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A.

    Clin Pharmacol Ther. 2007 Sep;82(3):275-81. Epub 2007 Mar 14.PMID: 17361126 [PubMed - indexed for MEDLINE]Related articles

    12.

    Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.

    Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E.

    Diabetes Care. 2008 Jan;31(1):121-7. Epub 2007 Oct 1.PMID: 17909084 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.

    Diabetes Care. 2006 May;29(5):1016-23.PMID: 16644631 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

    Sourij H, Zweiker R, Wascher TC.

    Diabetes Care. 2006 May;29(5):1039-45.PMID: 16644634 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

    Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM.

    Obes Res. 2002 Oct;10(10):1008-15. Erratum in: Obes Res. 2002 Nov;10(11):following table of contents.. PMID: 12376581 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.

    Shadid S, Jensen MD.

    Diabetes Care. 2003 Nov;26(11):3148-52.PMID: 14578253 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.

    McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF.

    Diabetes Care. 2005 May;28(5):1145-50.PMID: 15855580 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment.

    Kim SK, Hur KY, Kim HJ, Shim WS, Ahn CW, Park SW, Cho YW, Lim SK, Lee HC, Cha BS.

    Eur J Endocrinol. 2007 Aug;157(2):167-74.PMID: 17656594 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.

    Abe M, Kikuchi F, Kaizu K, Matsumoto K.

    Clin Nephrol. 2007 Nov;68(5):287-94.PMID: 18044260 [PubMed - indexed for MEDLINE]Related articles

    20.

    Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

    Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R.

    Clin Pharmacol Ther. 2006 Aug;80(2):105-14. Epub 2006 Jun 30.PMID: 16890572 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity